Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

a net loss of $66.9 million ($0.50 per share) in the fourth quarter of 2006. The fourth quarter 2007 net loss included $16.9 million ($0.13 per share) in expenses related to the licensing and collaboration agreement entered into with Aegera Therapeutics.

HIGHLIGHTS OF RECENT PROGRESS

Albuferon(R): On Track with Timeline to Phase 3 Data and Filing of Marketing Applications

On November 1, 2007, HGS announced that it completed enrollment ahead of schedule in ACHIEVE 2/3, the second of two pivotal Phase 3 clinical trials of Albuferon (albinterferon alfa-2b) in combination with ribavirin in treatment- naive patients with chronic hepatitis C. Enrollment in ACHIEVE 1 was also completed ahead of schedule, in August 2007. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

On January 23, 2008, HGS announced the modification of dosing in one arm of each of its ACHIEVE clinical trials based on recommendations made by the studies' independent Data Monitoring Committee (DMC). Patients in the Phase 3 trials who had been receiving the 1200-mcg dose are now receiving the 900-mcg dose, which HGS has viewed for some time as the dose of Albuferon most likely to be marketed. Consistent with its charter, the DMC will continue to review all adverse events on an ongoing basis as the ACHIEVE trials move forward.

The final results of Phase 2 trials of Albuferon were presented at the annual meeting of the American Association for the Study of Liver Diseases in November 2007. These results suggest that the 900-mcg dose of Albuferon every two weeks demonstrated efficacy and safety comparable to Pegasys, with half the injections, improvements in quality of life and fewer missed days of work on treatment. If these results are confirmed in Phase 3, HGS believes that Albuferon could become the market-leading interferon for the treatment of hepatitis C.

HGS
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Nematicide is a type of chemical ... parasitic roundworms, found in massive quantities virtually everywhere—in ... animals. Nematicides have tended to be broad-spectrum toxicants ... through the soil. A single gram of soil ... more than 10,000 species classified, they are one ...
(Date:9/30/2014)... 2014 Follow us on LinkedIn ... type of cholesterol carrier or lipoprotein in the blood. ... cholesterol levels in the body, especially along the walls ... attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) is ... cholesterol levels on a regular basis, to assess an ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... ... ... , , , ... ...
... ... web to cost effectively boost the pool of eligible patients for screening for any ... upload recruitment material approved by their Institutional Review Board (IRB), on their own specific ... ...
... ... ... ... ...
Cached Biology Technology:Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 2Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 3Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 4RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™ 2RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™ 3China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 2China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 3China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 4China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 5China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 6China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 7
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... wrong with your muscles because of age, disease or injury, ... That,s where a new research report published in the October ... comes in. In the report, a team of scientists produce ... scientists "see" which genes are active in an organ at ... and that men have approximately 400 more active genes in ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... National Institute of Standards and Technology (NIST) have ... clumps of proteins in protein-based pharmaceuticals. This first ... can be assured that their instruments are faithfully ... concern because of its impact on quality control ...
... laundry products and air fresheners found the products emitted ... off at least one chemical regulated as toxic or ... was listed on the product labels. , "I first ... me that the air fresheners in public restrooms and ...
... the first issue of , Energy & Environmental Science ... Free for all to read online, this inaugural ... hydrogen storage, thermochemical biofuel production, sustainable energy, and much ... of the highest quality, knowing that they can rely ...
Cached Biology News:NIST trumps the clumps: Making biologic drugs safer 2Toxic chemicals found in common scented laundry products, air fresheners 2Toxic chemicals found in common scented laundry products, air fresheners 3
...
...
... and supplies, for 10 chips, provides ... perform standard-sensitivity RNA analysis (nanogram levels) ... automated electrophoresis system. Supplied are 1,250 ... StdSens stain, 20 microliters RNA ladder, ...
... vectors are designed for enhanced translation of cloned ... rabbit reticulocyte lysate. The maps for pCITE-2b(+) and ... following exceptions: pCITE-2b(+) is a 3793 bp plasmid; ... and Xcm I sites. Subtract 7 bp from ...
Biology Products: